Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.
Quintiles' banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance. Read more >>
PPD and partner Shin Nippon Biomedical Laboratories (SNBL) have hit the ground running with their Japanese joint venture, closing a deal that will see them join forces in the country's growing market for clinical trials. Read more >>
POPULAR COMMENT THREADS
U.K. CRO Ergomed is expanding its share of the postmarketing services business, buying a medical information firm that fields patient queries for drug companies.
The European Medicines Agency has affirmed its January recommendation, calling for the suspension of more than 700 products tied to improprieties at a GVK Biosciences facility in India.
BioClinica has inked a deal with consulting firm Kinapse to help spread the adoption of its risk-based monitoring service, a targeted approach to keeping tabs on trials.
DaVita Clinical Research, which handles outsourced trials for the kidney care giant, is expanding its European presence, bringing in global experts to extend its network of R&D sites.
CRO giant Parexel has updated its technology for patient randomization and clinical supply management, touting the latest version as a valuable tool for speeding up the process of designing studies.
WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.
From Our Sister Sites
Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of ASCO with a bang, rolling out a slate of new studies spotlighting the growing body of evidence that their new immuno-oncology drugs will play a key role fighting a range of cancers.
Danish enzyme maker Novozymes is answering the call for alternatives to animal antibiotics by entering the market for probiotics--the so-called good bacteria that are believed to boost growth and prevent the buildup of bad bugs in animals' guts.